Kohua Biotechnology: Expected net loss of 580 to 740 million yuan in 2025.

Kohua Biotech announced that it is expected to incur a net loss of 5.8 billion to 7.4 billion yuan in the fiscal year 2025, compared to a loss of 6.41 billion yuan in the same period last year. During the reporting period, the company adhered to its established development strategy, deeply analyzed industry trends, continuously iterated its product matrix to strengthen its core competitiveness, actively expanded into both domestic and foreign markets, and promoted the upgrading of new businesses to ensure sustainable high-quality development of the company. The main factors affecting performance include: asset impairment provisions have a significant adverse impact on profits. Industry policies combined with intensified market competition, simultaneous declines in quantity and price, and significant pressure on the profit end.